{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:18:57Z","timestamp":1787663937667,"version":"build-2736575974"},"reference-count":64,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373437"],"award-info":[{"award-number":["82373437"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjuvant CDK4\/6 inhibitors improve outcomes in hormone receptor\u2010positive, HER2\u2010negative (HR+\/HER2\u2212) early breast cancer, yet some patients still experience recurrence. Early relapse in particular is associated with poor prognosis, but the timing and patterns of recurrence following this treatment remain undefined, limiting further therapeutic strategy development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We analyzed pivotal trials of adjuvant CDK4\/6 inhibitors in early\u2010stage HR+\/HER2\u2212 breast cancer to assess the temporal distribution of iDFS events. Invasive disease\u2010free survival (iDFS) and overall survival (OS) data were extracted from Kaplan\u2013Meier curves using PlotDigitizer. Events were evaluated up to 60\u2009months, a time frame with consistent follow\u2010up across trials. The primary endpoint was the proportion of early versus total iDFS events and deaths by 60\u2009months. The types and patterns of first iDFS event, as well as adverse events, were also discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 5\u2010year iDFS in CDK4\/6 inhibitor\u2010containing arms were as follows: 85.5% (NATALEE), 83.1% (monarchE), 84.2% (PALLAS), 67.9% (PENELOPE\u2010B). Early relapse\u2010related events (\u2264\u200936\u2009months) accounted for 63.5%, 63.9%, 62.7%, and 60.8% of total iDFS events, respectively, all proportions broadly similar to those observed in the control arms. The temporal distribution of iDFS event rates within consecutive 6\u2010month intervals appeared generally consistent. Distant metastasis constituted the predominant form of the first iDFS event, with bone as the most common metastatic site. The most frequently reported adverse events included neutropenia and diarrhea. Diarrhea was more prevalent with abemaciclib, whereas neutropenia occurred more frequently with palbociclib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjuvant CDK4\/6 inhibitors (ribociclib and abemaciclib) demonstrated iDFS benefits in monarchE and NATALEE. In our exploratory analysis, the temporal distribution of iDFS events appeared broadly consistent across trials, with no obvious concentration in any specific period. Given that early iDFS events (\u2264\u200936\u2009months) accounted for a substantial proportion of all events, further prospective studies are needed to optimize treatment for this high\u2010risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72224","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:49:11Z","timestamp":1787546951000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing and Patterns of Relapse\u2010Related Events Following Adjuvant\n                    <scp>CDK4<\/scp>\n                    \/6 Inhibitors Combined With Endocrine Therapy in Patients With\n                    <scp>HR<\/scp>\n                    \u2010Positive,\n                    <scp>HER2<\/scp>\n                    \u2010Negative Early Breast Cancer"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3905-7907","authenticated-orcid":false,"given":"Huihui","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Breast Surgery and Oncology The Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"},{"name":"Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6198-2701","authenticated-orcid":false,"given":"Shijie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology The Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"},{"name":"Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery The People's Hospital of Suichang County  Lishui China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology The Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"},{"name":"Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3701-0088","authenticated-orcid":false,"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"},{"name":"Zhejiang Provincial Clinical Research Center for Cancer  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2263-6275","authenticated-orcid":false,"given":"Yiding","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology The Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"},{"name":"Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-0330","authenticated-orcid":false,"given":"Yunxiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology The Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"},{"name":"Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01635-6"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.03.002"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.31083\/CEOG47264"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"e_1_2_12_7_1","unstructured":"Network NCC \u201cNational Comprehensive Cancer Network: Breast Cancer (version 5.2025) \u201d(2025) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01064"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2097067"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12571"},{"issue":"10","key":"e_1_2_12_12_1","article-title":"Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4\/6 Inhibitor) Plus Aromatase Inhibitors in Operable HER2\u2010Negative Luminal B Breast Cancer: A Prospective, Single\u2010Center, Single\u2010Arm, Phase II Trial (DANCER)","volume":"6","author":"Zhou Y.","year":"2025","journal-title":"MedCommunication"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213538"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.12.1501"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00747-x"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0661-5"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.07.002"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0305"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01562-9"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00172-9"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.003"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01994"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.015"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.515"},{"key":"e_1_2_12_32_1","first-page":"487","article-title":"Overall Survival With Abemaciclib in Early Breast Cancer","volume":"4","author":"Johnston S.","year":"2025","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105858"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30642-2"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.010"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1478"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8469"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12883-x"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.978985"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701830"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.534"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2025.01.04"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2238-3199"},{"key":"e_1_2_12_44_1","first-page":"1","article-title":"Post\u2010CDK4\/6 Inhibitor Treatment Landscape in Metastatic Hormone Receptor\u2010Positive Breast Cancer: A Narrative Review","volume":"25","author":"G\u00fcren A. K.","year":"2025","journal-title":"Expert Review of Anticancer Therapy"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.017"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00387-5"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00673-9"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404625"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03981-4"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00777-0"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104148"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32828-6"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa087"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.011"},{"issue":"15","key":"e_1_2_12_59_1","first-page":"235","article-title":"First\u2010Line Ribociclib (RIB) Plus Letrozole (LET) in Hormone Receptor\u2010Positive (HR+), HER2\u2010Negative (HER2\u2010) Advanced Breast Cancer (ABC): MONALEESA\u20102 Biomarker Analyses","volume":"36","author":"Hortobagyi G. N.","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy202"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0092-4"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103863"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2093719"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00694-5"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3700"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:24:42Z","timestamp":1787660682000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/cam4.72224"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72224","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72224"}}